News & Updates

Show Multimedia Only

Psoriatic arthritis weakens hand strength

12 Dec 2021

Patients with psoriatic arthritis exhibit reduced hand grip strength, with the deterioration of skill, coordination, and functionality of hand commensurate with the severity of psoriatic arthritis, a study has found.

12 Dec 2021

Guselkumab safe, well tolerated in patients with psoriatic arthritis

10 Dec 2021 by

Treatment with the monoclonal antibody targeting interleukin [IL]-23p19 guselkumab 100 mg, given either every 4 (Q4W) or 8 weeks (Q8W), is well tolerated in patients with psoriatic arthritis (PsA), with no new safety concerns through 1 year, according to pooled results of the DISCOVER-1 and DISCOVER-2 phase III trials.

10 Dec 2021

Ixekizumab effective for difficult-to-treat psoriatic arthritis

08 Dec 2021 by

The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.

08 Dec 2021

Regional anaesthesia advocated for certain patients undergoing knee replacement

02 Dec 2021 by

For patients undergoing primary unilateral total knee arthroplasty (TKA), regional anaesthesia results in a shorter stay in the hospital compared with general anaesthesia, especially among elderly patients and those with normal weight or obesity, as shown in a study from Singapore.

02 Dec 2021

What is the optimal tanezumab dose, administration route for osteoarthritis pain?

30 Nov 2021

Intravenous treatment with tanezumab at 10 mg achieves the highest efficacy in terms of relieving pain in patients with osteoarthritis (OA), according to the results of a network meta-analysis.

30 Nov 2021

Homocysteine tied to spinal osteoarthritis prevalence in postmenopausal women

28 Nov 2021

Circulating homocysteine and C677T variant in methylenetetrahydrofolate reductase (MTHFR) appear to influence the prevalence rate and ensuing progression of spinal osteoarthritis (OA), respectively, in postmenopausal women, a study has shown.

28 Nov 2021

Guselkumab yields durable benefit in biologic-naïve PsA patients

23 Nov 2021

The interleukin (IL)-23p19-subunit inhibitor guselkumab appears to produce improvements in multiple disease domains of psoriatic arthritis (PsA) with no unexpected safety findings through 2 years of treatment in biologic-naïve patients, according to the phase III DISCOVER-2 trial.

23 Nov 2021

Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis

22 Nov 2021

Chronic pain frequently occurs in patients with axial spondyloarthritis (axSpA), with no differences seen in any pain measures between those with ankylosing spondylitis (AS) and nonradiographic axSpA, a recent study has shown. In addition, higher pain sensitivity is predictive of having worse disease and health outcomes.

22 Nov 2021

Colchicine cessation possible in familial Mediterranean fever with prolonged remission

21 Nov 2021

Colchicine therapy may be discontinued after prolonged remission in some children with familial Mediterranean fever (FMF), suggests a study, noting, however, that patients with arthritis or myalgia are prone to an attack following treatment cessation.

21 Nov 2021

Belimumab benefit sustained regardless of lupus nephritis status

15 Nov 2021 by

The recombinant human IgG-1λ monoclonal antibody belimumab improved renal outcomes in patients with relapsed and newly diagnosed* active lupus nephritis (LN), according to subgroup analysis results of the BLISS-LN** trial presented at ASN 2021.

15 Nov 2021